Shots:
- Regeneron has entered into an in-licensing agreement with Hansoh for exclusive global clinical development & commercialization rights of HS-20094, excl. Mainland China, Hong Kong & Macau
- As per the deal, Hansoh will receive $80M upfront & ~$1.93B in development, regulatory & sales milestones, with low double digits royalties on sales in Regeneron-licensed areas
- HS-20094 (SC, QW), a dual GLP-1/GIP receptor agonist, is being evaluated in an ongoing P-III trial for obesity in China & a P-IIb study for diabetes
Ref: Regeneron| Image: Regeneron & Hansoh Pharma| Press Release
Related News:- Regeneron and Sanofi Report P-III (AERIFY-1 & AERIFY-2) Trials Data of Itepekimab for Chronic Obstructive Pulmonary Disease (COPD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
